论文部分内容阅读
自1983年异维A酸在加拿大上市至2005年底,加拿大卫生部收到29例与异维A酸有关的心血管不良反应报告。其中11例为心肌梗死、卒中及血栓栓塞性疾病。这些不良反应在加拿大药品专论中未予标明。11例中男性4例,女性7例,用法用量为40~80m g/d,4d~8m o。转归:8例恢复(1例有后遗症),
Since isotretinoin was marketed in Canada by 1983 and by the end of 2005, Health Canada received 29 reports of cardiovascular adverse effects associated with isotretinoin. Eleven of them were myocardial infarction, stroke and thromboembolic diseases. These adverse reactions are not indicated in Canadian monographs. Among the 11 cases, there were 4 males and 7 females. The dosage was 40 ~ 80 m g / d and 4 d ~ 8 m o. Outcome: 8 cases of recovery (1 case of sequelae),